European advisory group backs seven medicines for approval, rejects Repros' enclomiphene [Seeking Alpha]
Royalty Pharma plc - Class A Ordinary Shares (RPRX)
US:NASDAQ Investor Relations:
ir.reprosrx.com/investor-relations
Company Research
Source: Seeking Alpha
European advisory group backs seven medicines for approval, rejects Repros' enclomipheneThe European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adoptedpositive opinions backing the approval for the following drugs:Roche's (OTCQX:RHHBY)Hemlibra (emicizumab) to prevent bleeding episodes in hemophilia A patients who have factor VIII inhibitors.Chiesi Farmaceutici S.A.'s enzyme replacement therapyLamzede (velmanase alfa) for the treatment of non-neurological manifestations of mild-to-moderate alpha-mannosidosis.GlaxoSmithKline's (NYSE:GSK) shingles vaccineShingrix (recombinant, adjuvanted Herpes zoster vaccine).Merck's (NYSE:MRK)Segluromet (ertugliflozin and metformin) for type 2 diabetes (T2D),Steglatro (ertugliflozin) for T2D andSteglujan (ertugliflozin and sitagliptin) for T2D.Mylan's (NASDAQ:MYL) Semglee (insulin glargine), a biosimilar of Sanofi's (NYSE:SNY)Lantus.Positive opinion confirmed for AstraZeneca'sLokelma (sodium zirconium cyclosilicate) fo
Show less
Read more
Impact Snapshot
Event Time:
RPRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RPRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RPRX alerts
High impacting Royalty Pharma plc - Class A Ordinary Shares news events
Weekly update
A roundup of the hottest topics
RPRX
News
- Insights Into Royalty Pharma (RPRX) Q1: Wall Street Projections for Key Metrics [Yahoo! Finance]Yahoo! Finance
- Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be $0.21 [Yahoo! Finance]Yahoo! Finance
- Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma [Yahoo! Finance]Yahoo! Finance
- Royalty Pharma (NASDAQ:RPRX) Will Pay A Dividend Of $0.21 [Yahoo! Finance]Yahoo! Finance
- Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024GlobeNewswire
RPRX
Sec Filings
- 4/25/24 - Form ARS
- 4/25/24 - Form DEFA14A
- 4/25/24 - Form DEF
- RPRX's page on the SEC website